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Bordi Licia et al.* 
Laboratory of Virology, National Institute for Infectious Diseases “L. Spallanzani”, Rome 
Italy 
1. Introduction 
Until recently, very few physicians in industrialized countries had heard the word 
“Chikungunya”, and fewer knew how to spell it. Chikungunya, a viral infection transmitted 
by mosquitoes, derives its name from Makonde, a language spoken in south Tanzania, and 
means “that which bends up”, referring to the posture of patients afflicted with severe joint 
paints characterizing this infection. Chikungunya virus (CHIKV) was first isolated in 
Tanzania in 1952 (Robinson, 1955) and has come to the world attention recently, when it 
caused a massive outbreak in the Indian Ocean region and India (Enserik, 2006). Since 1952, 
CHIKV has caused a number of epidemics, both in Africa and Southeast Asia, many of them 
having involved hundreds-of-thousands people. In 2005 the largest Chikungunya fever 
epidemic on record occurred. The most affected region was La Reunion Island, where 
CHIKV infected more than a third of the population and killed hundred of people. The 
2005/2006 outbreak, started from Comoro Islands, rapidly spread to several countries in the 
Indian Ocean and India (Enserik, 2006; Mavalankar et al., 2007). Compared to earlier 
outbreaks, this episode was massive, occurred in highly medicalized areas such as La 
Reunion, and had very significant economic and social impact. More than 1000 imported 
CHIKV cases have been detected among European and American travellers returning from the 
affected areas since the beginning of the outbreak in the Indian Ocean region (Fusco et al., 
2006; Taubiz et al., 2007), giving rise, in 2007, to the first autochthonous European outbreak in 
Italy (Charrel & de Lambellerie, 2008; Rezza et al., 2007). Since 2006, the Regional Office of the 
French Institute For Public Health Surveillance in the Indian Ocean has conducted 
epidemiological and biological surveillance for CHIKV infection. During the period December 
2006-july 2009, no confirmed case was detected on Reunion Island and Mayotte, but new 
outbreak were reported in Madacascar. After few years of relative dormancy in Réunion 
Island, CHIKV transmission has restarted in 2009 and 2010, with one case imported in France 
(May 2010) (D’Ortenzio et al., 2010). This episode has refreshed the concerns about the 
possibility of renewed autochthonous transmission in Mediterranean countries. 
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2. Microbiology 
CHIKV is an alphavirus belonging to the Togaviridae family. Alphaviruses are small and 
spherical, with a 60-70 nm diameter capsid and a phospholipid envelope. The RNA  single-
strand of positive polarity encodes four non structural proteins (nsP1-4) and three structural 
proteins (C,E1,E2). Viral replication is initiated from the time of attachment of viral envelope 
to cellular host receptors (Strauss & Strauss, 1994). Endocitosis of the virus occurs, following 
which, delivery of the viral nucleocapsid into cytoplasm takes place. The replication cycle is 
considerably fast, taking around 4hours. Alphaviruses are sensitive to disseccation and to 
temperatures above 58°C (Khan et al., 2002; Strauss J.H. & StraussE.M., 1994). About 30 
species of arthropod-borne viruses are included in the alphavirus genus, antigenically 
classified into 7 complexes. These viruses are widely distributed throughout the world, with 
the exception of Antarctica, and 7 of them cause a syndrome similar to Chikungunya fever, 
arthralgia and rash: Barmah Forest and Ross river viruses (Oceania), O’nyong-nyong and 
Semliki Forest viruses (Africa), Mayaro (South America), Sindbis and Sindbis-like (Africa, 
Asia, Scandinavia and Russia) (Taubiz et al., 2007). 
3. Vector and reservoir 
In Asia and the Indian Ocean region the main CHIKV vectors are A. aegypti and A. 
albopictus.( Jeandel et al. 2004 ; Zeller, 1998). A larger range of Aedes species (A. furcifer, A. 
vittatus, A. fulgens, A. luteocephalus, A. dalzieli, A. vigilax, A. camptorhynchites) transmit the 
virus in Africa, and Culex annulirostris, Mansonia uniformis, and anopheles mosquitoes have 
also occasionally been incriminated (Jupp P.G. et al., 1981; Jupp P.G. & McIntosh, 1990; Lam 
et al., 2001;). In India, the dominant carrier of Chikungunya virus is A. aegypti, which breeds 
mainly in stored fresh water in urban and semi-urban environments (Yergolkar, 2006).  
A. albopictus has a wide geographical distribution, is particularly resilient, and can survive in 
both rural and urban environments. The mosquito’s eggs are highly resistant and can 
remain viable throughout the dry season, giving rise to larvae and adults the following 
rainy season. Originating from Asia, and initially sylvatic, A. albopictus has shown a 
remarkable capacity to adapt to human beings and to urbanisation, allowing it to supersede 
A. aegypti in many places, and to become a secondary but important vector of dengue and 
other arboviruses (Knudsen, 1995). A. albopictus is zoophilic and anthropophilic, is 
aggressive, silent, active all-day long, and has a lifespan longer than other mosquitoes (up to 
8 weeks) and, in the last decades has expanded to several areas previously known to be 
Aedes-free (Charrel et al., 2007). It seems that most new introductions of A. albopictus have 
been caused by vegetative eggs contained in timber and tyres exported from Asia 
throughout the world. Other emerging events also contributed to the introduction of A. 
albopictus mosquitoes into previously unaffected areas, such as climate change and the 
increasing use of plastic containers in developing countries. Indeed, climate changes may 
have several effects on vector biology: increasing temperatures may improve survival at 
higher latitudes and altitudes, increase the growth rates of vector populations, and alter 
their seasonality; increased rainfall may have an effect on the larval habitat and population 
size, and finally an increase in humidity could favourably affect vector survival (Gubler et 
al., 2001). The use of plastic containers in developing countries, where they are usually not 
correctly disposed and remain in the environment for years, has also been linked with the 
spread of the mosquitoes: acting as rain-water receptacles, and being exposed to sunlight, 
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they can become perfect “incubators” for mosquito eggs, where the ideal conditions of 
temperature and humidity are achieved easily and naturally.  
Human beings serve as the Chikungunya virus reservoir during epidemic periods. In Africa 
some animals (monkeys, rodents, and birds) constitute the virus reservoir during not-epidemic 
periods, sustaining virus circulation in the environment in the absence of human cases. 
Outbreaks might occur in monkeys when herd immunity is low; the animals develop viraemia 
but no pronounced physical manifestations (Inoue et al., 2003; Wolfe et al., 2001). An animal 
reservoir has not been identified in Asia, where humans appear to be the only host.   
4. Clinical manifestation  
4.1 General features  
After infection with Chikungunya virus, there is a silent incubation period lasting 2–4 days 
on average (range 1–12 days) (Lam et al., 2001).  Clinical onset is abrupt, with high fever, 
headache, back pain, myalgia, and arthralgia; the latter can be intense, affecting mainly the 
extremities (ankles, wrists, phalanges) but also the large joints (Hochedez et al., 2006; Lam et 
al., 2001; Quatresous, 2006; Robinson, 1955; Saxena et al., 2006). Skin involvement present in 
about 40–50% of cases, and consists of (1) a pruriginous maculopapular rash predominating 
on the thorax, (2) facial oedema, or (3) in children, a bullous rash with pronounced 
sloughing, and (4) localised petechiae and gingivorrhagia (mainly in children) (Brighton et 
al., 1983; Fourie & Morrison, 1979). Radiological findings are normal, and biological markers 
of inflammation (erythrocyte sedimentation rate and C-reactive protein) are normal or 
moderately elevated (Fourie & Morrison, 1979; Kennedy et al., 1980). Iridocyclitis and 
retinitis are the most common ocular manifestations associated with Chikungunya fever; 
less frequent ocular lesions include episcleritis. All ocular manifestations have a benign 
course with complete resolution and preservation of vision. Retinitis shows gradual 
resolution over a period of 6 to 8 weeks (Mahendradas et al., 2008). CHIKV infection seems 
to elicit long-lasting protective immunity, and experiments performed using animal models 
have shown a partial cross-protection among CHIKV and other alphaviruses (Edelman et 
al., 2000; Hearn  Jr. & Rainey, 1963). 
4.2 Arthralgia 
Erratic, relapsing, and incapacitating arthralgia is the hallmark of Chikungunya, although it 
rarely affects children. These manifestations are normally migratory and involve small joints 
of hands, wrists, ankles, and feet with pain on movement. Symptoms generally resolve 
within 7–10 days, except for joint stiffness and pain: up to 12% of patients still have chronic 
arthralgia three years after onset of the illness. Arthralgia experienced by CHIKF patients 
closely resembles the symptoms induced by other viruses like Ross River Virus (RRV) and 
Barmah Forest virus (BFV) (Jacups et al, 2008; Mahalingam et al., 2002). Such alphavirus-
induced arthralgia mirrors rheumatoid arthritis, a condition which is characterised by 
severe joint pains due to inflammation and tissue destruction caused by inflammatory 
cytokines such as IL-1b, IL-6 and TNF-a (Barksby et al., 2007). It is thus plausible that 
CHIKV infection induces similar pro-inflammatory cytokines that cause arthralgia, 
explaining why joint pains are constant ailments of many patients infected with CHIKV 
even years after recovery from the initial febrile phase (Lakshmi et al., 2008). More 
recently, global analyses on the specific involvement of cytokines and chemokines have 
showed that IL-1b, IL-6, and RANTES were associated with disease severity (Ng et al., 
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2009). Moreover, since high concentrations of these pro-inflammatory factors were found 
in the joints of humans afflicted with RRV-induced polyarthritis, they probably have a 
causative role in chronic joint and muscle pains that plague patients (Lidbury et al., 2008). 
The finding that aberrant Type I interferon signalling in mice led to severe forms of 
CHIKF (Couderc et al., 2008) further highlighted the important role cytokines play in the 
pathology of CHIKV infection. 
4.3 Other pathologies 
Chikungunya is not generally considered to be a life-threatening disease. Usually the clinical 
course is fairly mild, but fatal cases directly or indirectly linked to infection with CHIKV 
have been observed during the Indian-Ocean outbreak (Josseran et al., 2006). The main 
evidence of a mortality linked to Chikungunya fever epidemics has been obtained in La 
Reunion, Mauritius, and India by comparing expected and observed mortality data. In all 
cases, during the months when the epidemics were raging, the observed mortality 
significantly exceeded the expected one. In particular, in La Reunion the monthly crude 
death rates in February and March 2006 were 34.4%and 25.2% higher, respectively, than 
expected. These corresponded to 260 excess deaths (an increase of 18.4%) with a rough 
estimate of the case-fatality rate for Chikungunya fever of ≈1/1,000 cases. The case-fatality 
rate calculated on increased crude death rates in Mauritius and Ahmedabad, India, is 
substantially higher than that calculated in La Reunion: approximately 4.5% (15,760 
confirmed or suspected cases and 743 excess deaths) and 4,9% (60,777confirmed or 
suspected cases and 2,944 excess deaths), respectively (Beesoon et al., 2008; Mavalankar et 
al., 2008). These differences may be attributed to many factors (greater disease severity, 
preexisting patient conditions, different patient management, or coincident excess deaths 
from other causes) but may also be due to a different efficacy of the surveillance systems for 
Chikungunya fever, that probably worked poorly in Mauritius and India, leading to 
underestimating the total number of cases (Fusco et al., 2010). The possible link between 
CHIKV infection and multiorgan failure is still under investigation.  
Neurological complications such as meningo-encephalitis were reported in a few patients 
during the first Indian outbreak in 1973, and during the 2006 Indian outbreak (Chatterjee et 
al., 1965; Ravi, 2006). The possible mechanisms underlying these processes remain 
unknown. Studies performed on animal models showed that CHIKV-infected young mice 
had weakness and walking difficulties which could be due to necrosis and inflammation of 
skeletal muscles (Ziegler et al., 2008). CHIKV antigens and viral replication have been 
detected in human myogenic precursors such as satellite cells but not in muscle fibers 
(Ozden et al., 2007), suggesting that muscle satellite cells could be potential virus reservoirs. 
The pathologic symptoms of encephalitis owing to CHIKV infection as well as central 
nervous system (CNS) infections (Chatterjee &  Sarkar, 1965) were expected, since in vitro 
experiments showed that the virus could infect and replicate for extended periods in mouse 
brain cells (Precious et al., 1974). More recently, it was found that mouse CNS tissues such as 
the choroid plexi could also be targets of CHIKV, lending more credence to the fact that 
CHIKV infections do affect CNS cells and tissues (Couderc et al., 2008). Work is currently 
underway by several research groups around the world to decipher this mechanism in 
CHIKV infections. Moreover, during the 2006 Indian-Ocean outbreak, rare cases of Guillain-
Barré syndrome (GBS) associated with CHIKV infection have been described (Lebrun et al., 
2009; Wielanek et al., 2007). 
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Other rare complications described after CHIKV infection are mild hemorrhage, 
myocarditis, hepatitis (Lemant et al., 2008) .  
5. Diagnosis 
Diagnosis of infection with CHIKV is based on molecular biology (RT-PCR) and serology 
methods. The first one is useful during the initial viraemic phase, at the onset of symptoms 
and normally for the following 5-10 days, when CHIKV RNA reaches very high levels (viral 
loads of 3.3 x 109 copies/ml) and can be detected (Carletti et al., 2007; Parola et al., 2006). 
Afterwards, the diagnosis is based on serological methods (ELISA, immunofluorescence, 
hemoagglutination inhibition (HI) and infectivity neutralization (Nt)). 
IgM specific against CHIKV are detectable 2-3 days after the onset of symptoms by ELISA 
immunofluorescent assay and persists for several weeks, up to 3 months (Litzba et al, 2008; 
Sam & AbuBakar, 2006); rarely, IgM can be detected for longer periods, up to 1 year.  IgG 
specific against CHIKV appear soon after IgM antibodies (2-3 days) and persists for years. 
Testing of a couple of sera collected in the acute and the convalescent phases of the disease 
is mandatory for the identification of recent infection using serology methods that cannot 
distinguish IgG Ab from IgM Ab (i.e. HI and Nt). It is also very useful to confirm results 
obtained with other methods, especially taking into account the although rare persistence of 
IgM antibodies. Viral isolation can be performed from serum of infected patient on insect or 
mammalian cell lines (i.e. C6/36 or Vero E6) during the early phase of the disease, when the 
viral load is very high and the immune response is still not detectable; however it is useful 
only for epidemiology or pathogenesis studies or for thorough molecular characterization 
(Fusco et al., 2010). The sensitivity and specificity of rapid bedside tests commercially 
available are poorly established, and the possibility of false-positive reactions resulting from 
cross-reactivity with dengue or other arboviruses such as o’nyong-nyong virus has to be 
considered (Blackburn et al., 1995). Serologically, chikungunya virus is most closely related 
to o’nyong-nyong virus and is a member of the Semliki Forest antigenic complex. Individual 
serological testing is not particularly useful, except when faced with atypical or severe 
forms, or in travellers returning from an epidemic zone (Pile et al., 1999).  
6. Treatment 
Currently, there are no available specific therapeutics against CHIKV. Treatment is purely 
symptomatic and can include rest, fluids, and medicines to relieve symptoms of fever and 
aching, such as ibuprofen, naproxen, acetaminophen, or paracetamol. Non-steroidal anti-
inflammatory drugs (NSAIDs) are primarily used to treat inflammation but high doses, 
administrated to control arthralgia, could cause thrombocytopenia, gastrointestinal 
bleeding, nausea, vomiting and gastritis (Jain et al, 2008;  Pialoux et al., 2007). Steroids have 
been occasionally used but their efficacy was not significant (Taubitz et al., 2007). Some time 
ago chloroquine, a drug useful for prophylaxis and treatment of malaria, showed promising 
results for treating chronic Chikungunya arthritis (Brighton, 1984), while a recent trial 
conducted on French Reunion Island proved that there is currently no justification for the 
use of chloroquine to treat acute chikungunya diseases (De Lamballerie et al., 2008). 
However, the usefulness of chloroquine in the treatment of Chikungunya infection deserves 
further investigation that could take advantage on the availability of a non-human primate 
animal model (Labadie et al., 2010). Ribavirin (200 mg twice a day for seven days) given to 
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patients who continued to have crippling lower limb pains and arthritis for at least two 
weeks after a febrile episode, had a direct antiviral property against CHIKV, leading to 
faster resolution of joint and soft tissue manifestations (Ravichandran & Manian, 2008). 
Briolant and collegues screened various active antiviral compounds against viruses of the 
Alphavirus genus in vitro and demonstrated that 6-azauridinet was more effective against 
CHIKV, as compared to ribavirin. Moreover, the combination of IFN-alpha2b and ribavirin 
had synergistic antiviral effect on Chikungunya virus (Briolant et al., 2004). 
It is widely recognized that passive vaccination is an appropriate preventive and therapeutic 
option for many viral infections in human, including those spread by viral vertical 
transmission, especially when no alternative therapy is available (Dessain et al., 2008). 
Human polyvalent immunoglobulins purified from plasma samples obtained from donors 
in the convalescent phase of CHIKV infection exhibited a high in vitro neutralizing activity 
and a powerful prophylactic and therapeutic efficacy against CHIKV infection in vivo in 
mouse models (Couderc et al., 2009). Due to the demonstrated efficacy of human anti-
CHIKV antibodies in a mouse model, purified polyvalent CHIKIg (commercialized under 
the brand Tégéline) could be used in humans for prevention and treatment, especially in 
individuals at risk of severe CHIKV disease, such as neonates born to viraemic mothers and 
adults with underlying conditions. Polyclonal immune globulins present the advantage of a 
broad reactivity but the therapeutic intervention is limited, due to the short viremia in acute 
phase of CHIKV infection: thus the only benefit this treatment has to offer would be to help 
reducing viremia faster (Kam et al., 2009). As an alternative, more specific human 
monoclonal antibodies (MAbs) could be used. In a recent study two unique human mAbs, 
specific for the CHIKV envelope glicoproteins, strongly and specifically neutralized CHIKV 
infection in vitro (Warter et al., 2011). 
7. Prevention 
Although no licensed vaccines are currently available for CHIKV, potential vaccine 
candidates have been tested in humans and animals with varying success. Due to the 
easiness in preparation, the first developed vaccines were formulations of whole-virus grew 
on cells and inactivated either by formalin or tween-ether (Eckels et al., 1970; Harrison et al., 
1967, 1971; White et al.,  1972). 
Further vaccines are focused on attenuated strains of CHIK obtained after serial passages in 
cells cultures (Edelman et al., 2000; Levitt et al., 1986). One of these promising candidates is 
TSI-GSD-218, a serially passaged and plaque-purified live CHIK vaccine, tested for safety 
and immunogenicity in human Phase II trials by the US Army Medical Research Institute 
(Edelman et al., 2000). Seroconversion was obtained in 98% of vaccinees volunteers by day 
28 and neutralizing antibodies persisted in 85% of cases at one year after immunization. 
However transient arthralgia occurred in 8% of the volunteers. Some chimeric candidates 
vaccines were developed using either Venezuelan equine encephalitis (VEEV) attenuated 
vaccine strain TC-83, a naturally attenuated strain of eastern equine encephalitis virus 
(EEEV), or Sindbis virus (SV) as a backbone and the structural protein genes of CHIKV. 
Vaccinated mice were fully protected against disease and viraemia after CHIKV challenge 
(Wang et al., 2008). The maturity of reverse genetic technology has provided unprecedented 
opportunities for manipulation of the alphaviral genome to improve attenuation strategies. 
Thus, unlike traditional attenuation approaches that rely on cell culture passages, which 
typically result in attenuation that depends only on small numbers of attenuating point 
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mutations, alternative genetic strategies such as viral chimeras offer the promise of more 
stable attenuation (Kennedy et al., 2011). In addition to the risk of reactogenicity, attenuation 
based on small numbers of mutations can also result in residual alphavirus infectivity for 
mosquito vectors. This risk, which was underscored by the isolation of the TC-83 VEEV 
vaccine strain from mosquitoes in Louisiana during an equine vaccination campaign 
designed to control the 1971 epidemic (Pedersen et al., 1972), is especially high when a 
vaccine that relies on a small number of point mutations is used in a nonendemic location 
that could support a local transmission cycle. In a recent study chimeric alphaviruses, 
encoded CHIKV-specific structural genes (but no structural or nonstructural proteins 
capable of interfering with development of cellular antiviral response) induced protective 
immune response against subsequent CHIKV challenge (Wang et al., 2011). More in detail, 
recombinant chikungunya virus vaccine, comprising a non-replicating complex adenovirus 
vector encoding the structural polyprotein cassette of chikungunya virus, consistently 
induced in mice high titres of anti-chikungunya virus antibodies that neutralised both an 
old Asian isolate and a Réunion Island isolate from the recent epidemic (Wang et al., 2011).  
A novel CHIK vaccine candidate, CHIKV/IRES, was generated by manipulation of the 
structural protein expression of a wt-CHIKV strain via the EMCV IRES (Plante et al., 2011). 
In particular, the internal ribosome entry site (IRES) from encephalomyocarditis virus 
replaced the subgenomic promoter in a cDNA CHIKV clone, thus altering the levels and 
host-specific mechanism of structural protein gene expression. This vaccine candidate 
exhibited a high degree of murine attenuation that was not dependent on an intact 
interferon type I response, highly attenuated and efficacious after a single dose. 
Another approach was the selective expression of CHIK viral structural proteins recently 
obtained by Akata and collegues using virus-like particles (VLPs) in vitro, that resemble 
replication-competent alphaviruses (Akahata et al., 2010). Immunization of monkeys with 
these VLPs elicited neutralizing antibodies against envelope proteins from different 
CHIKV strains and obtained antibodies transferred into mice protective against 
subsequent lethal CHIKV challenge. The last frontier in the approach of CHIK vaccine 
design is the DNA vaccine strategy. An adaptive constant-current electroporation 
technique was used to immunize mice (Muthumani et al., 2008) and rhesus macaques 
(Mallilankaraman et al., 2011) with an intramuscular injection of plasmid coding for the 
CHIK-Capsid, E1 and E2. Vaccination induced robust antigen-specific cellular and 
humoral immune responses in either case.   
To date a number of CHIKV vaccines have been developed, but none have been licensed. 
While a number of significant questions remain to be addressed related to vaccine 
validation, such as the most appropriate animal models (species, age, immune status), the 
dose and route of immunization, the potential interference from multiple vaccinations 
against different viruses, and last, the practical cost of the vaccine, since most of the 
epidemic geographical regions belong to the developing countries, there is real hope that a 
vaccine to prevent this disease will not be too long in arriving.  
Since a vaccine is not available actually, protection against mosquito bites and vector control 
are the main preventive measures. Individual protection relies on the use of mosquito 
repellents and measures in order to limit skin exposure to mosquitoes. Bednets should be 
used during the night in hospitals and day-care facilities but Aedes mosquitoes are active all-
day-long. Control of both adult and larval mosquito populations uses the same model as for 
dengue and has been relatively effective in many countries and settings. Breeding sites must 
be removed, destroyed, frequently emptied, and cleaned or treated with insecticides. Large-
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scale prevention campaigns using DDT have been effective against A. aegypti but not A. 
albopictus. Control of A. aegypti has rarely been achieved and never sustained (Reiter et al., 
2006). Recent data show the different degrees of insecticide resistance in A. albopictus and A. 
aegypti (Cui et al., 2006). However, vector control is an endless, costly, and labour-intensive 
measure and is not always well accepted by local populations, whose cooperation is crucial. 
Control of CHIKV infection, other than use of drugs for treatment of disease, development 
of vaccines, individual protection from mosquitoes and vector control programs, also 
involves surveillance that is fundamental for early identification of cases and quarantine 
measurement. A model used in investigation of the transmission potential of CHIKV in Italy 
has proven useful to provide insight into the possible impact of future outbreaks in 
temperate climate regions and the effectiveness of the interventions performed during the 
outbreak (Poletti et al., 2011). 
8. Geographic distribution and map 
Chikungunya fever has an epidemiological pattern with both sporadic cases and epidemics 
in west Africa, from Senegal to Cameroun, and in many other African countries (Democratic 
Republic of Congo, Nigeria, Angola, Uganda, Guinea, Malawi, Central African Republic, 
Burundi, and South Africa). Moreover, many epidemics occurred in Asia (Burma, Thailand, 
Cambodia, Vietnam, India, Sri Lanka, Timor, Indonesia, and the Philippines) in the 1960s 
and in the 1990s (Jain et al., 2008; Pialoux et al., 2007).  
Major epidemics appear and disappear cyclically, usually with an inter-epidemic period 
ranging from 7 to 20 years. The huge outbreak that increased concern about CHIKV started 
in Kenya in 2004, where the seroprevalence rates reached 75% in Lamu island (Pialoux et al., 
2007), before reaching the Comores, Seychelles, and Mauritius islands. The virus reached La 
Reunion island, a French overseas district, in March–April 2005, probably as a result of 
importation of cases among immigrants from the Comores. The outbreak had two phases: 
after some thousands of cases which occurred in March-April 2005, very few cases were 
reported during the austral winter, while the second epidemic peak arose in the initial 
months of 2006. For the first time, a substantial number of deaths (254) were attributed, 
directly or indirectly, to CHIKV. From late 2005 onwards, hospitals in some Indian states 
found themselves swamped with patients complaining of fever and joint pain, which turned 
out to be Chikungunya fever (Fusco et al., 2010). The World Health Organization Regional 
Office for South-East Asia has reported that 151 districts in nine states/provinces of India 
have been affected by Chikungunya fever between February and October 2006 (Pialoux et 
al., 2007). 
Several imported cases were reported in industrialized countries among travellers returning 
from endemic areas, mainly tourists and immigrants (Depoortere & Coulombier, 2006). In 
particular, many cases were detected in early 2006, when the outbreak involved the Indian 
Ocean islands. The Indian Ocean islands, India, and Malaysia are popular tourist 
destinations. According to the World Tourism Organization, an estimated 1 474 218 people 
travelled from Madagascar, Mauritius, Mayotte, Reunion, and the Seychelles to European 
countries in 2004 (Depoortere & Coulombier, 2006; Parola et al., 2006).  
The European country with the highest number of imported cases was France, especially the 
south-eastern region of Provence-Alpes-Côte d’Azur, and Marseille in particular, home to a 
large Comorian community (Cordel et al., 2006; Hochedez et al., 2007). Other European 
countries that reported imported cases include Belgium, Bosnia, Czech Republic, Croatia, 
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Germany, Greece, Italy, Serbia, Spain, Switzerland, Norway, and the United Kingdom 
(Beltrame, A. 2007; Deporteere & Coulombier, 2006; Fusco, F.M. 2006; Pialoux et al., 2007; 
Taubitz et al., 2007). In 2006, CHIK fever cases have also been reported in traveller 
returning from known outbreak areas to Canada, the Caribbean (Martinique), and South 
America (French Guyana). During 2005-2006, 12 cases of CHIK fever were diagnosed 
serologically and virologically at CDC in travellers who arrived in the United States from 
areas known to be epidemic or endemic for CHIK fever, and 26 additional imported cases 
with onset in 2006 underscores the importance of recognizing such cases among travellers 
(CDC, 2006; CDC 2007). 
Moreover, CHIKV gave rise in 2007 to the first autochthonous European outbreak in Italy, in 
the northern region of Emilia-Romagna (Rezza et al., 2007; Charrel et al., 2008). 
In June 2007, an Indian citizen returned to Italy after a visit to relatives in Kerala, India, 
developed 2  episodes of fever. During the second febrile episode, he visited his cousin in 
Castiglione di Cervia. The cousin had an onset of symptoms, with fever and arthralgia, on 
July 4. This sequence of events started the first Chikungunya fever outbreak in a temperate 
country, that lasted approximately 2 months with a total 247 cases of Chikungunya fever 
occurred in the region (217 laboratory-confirmed, 30 suspected) (Fusco et al., 2010). A 
unique sequence of events seems to have contributed to the establishment of local 
transmission in Emilia-Romagna: the high concentration of competent vectors A. albopictus 
in the area at the time of arrival of the index case, the presence of a sufficient human 
population density and the temporal overlapping of arthropod activity (seasonal 
syncronicity) (Charrel et al., 2008; Rezza et al., 2007). 
During 2008, cases of Chikungunya fever have been reported from many countries in Asia 
other than India, as well as active epidemics from Singapore, Sri Lanka, and Malaysia (Leo 
et al., 2009).  
Since 2006, the Regional Office of the French Institute For Public Health Surveillance in the 
Indian Ocean has conducted epidemiological and biological surveillance for CHIKV 
infection. During the period December 2006-July 2009, no confirmed case was detected on 
Reunion Island and Mayotte, but new outbreaks were reported in Madacascar. After few 
years of relative dormancy in Réunion Island, in August 2009, a cluster of cases was 
identified on the western coast of Réunion Island (D’Ortenzio et al., 2009) and, 
subsequently, an outbreak of CHIKV infection was described on Réunion Island in 2010 
(D’Ortenzio et al., 2011). Moreover, recent publications described cases of Chikungunya 
fever in tourist returning from Maldives, confirming the circulation of the virus by the end 
of 2009 (Pfeffer et al., 2010; Receveur et al., 2010) 
These episodes have refreshed the concerns about the possibility of renewed autochthonous 
transmission in Mediterranean countries and highlight the need for surveillance in countries 
where emerging infections may be introduced by returning travellers. Travellers can serve 
as sentinel population providing information regarding the emergence or re-emergence of 
an infectious pathogen in a source region. Travellers can thus act as carriers who 
inadvertently ferry pathogens that can be used to map the location, dynamics and 
movement of pathogenic strains (Pistone et al, 2009). Thus, with the increase in 
intercontinental travel, travellers can provide insights into the level of the risk of 
transmission of infections in other geographical regions.  
The geographic range of CHIKV is mainly in Africa and Asia (Fig. 1)  
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Fig. 1. Geographical distribution of CHIKV shown in the most recent map coming from the 
CDC’s Traveler’s Health website (http://wwwn.cdc.gov/travel/default.aspx).  
9. Phylogenesis 
Three lineages of CHIKV, with distinct genotypic and antigenic characteristics, have been 
identified. Isolates that caused the 2004-06 Indian Ocean outbreak form a distinct cluster 
within the large eastern and central Africa phylogenetic group, in addition to the Asian and 
west African phylogenetic groups (Powers et al., 2000; Schuffenecker et al., 2006).  
Phylogenetic analysis of CHIKV strains circulating in A. Albopicus-humans transmission 
cycles, obtained during outbreaks, have identified the independent acquisition of a common 
mutation in E1 glycoprotein (E1gp), namely A226V, in strains isolated from different 
geographic regions (Schuffenecker et al., 2006; de Lambellerie et al., 2008). This mutation, 
together with M269V, D284E mutations of E1 CHIKV glycoprotein have been described as 
molecular signatures of the Indian Ocean outbreak (Arankalle et al., 2007; Tsetsarkin et al., 
2007; Vazeille at al., 2007). In particular, the A226V mutation, which was absent in the 
strains isolated during the initial phases of the outbreak in Réunion, appeared in >90% of 
the isolates after Dicember 2005. This change could be related to virus adaptation to the 
mosquito vector species. Together with the lack of herd immunity, this might explain the 
abrupt and escalating nature of the Reunion outbreak. Has been clearly demonstrated that 
the A226V mutation is able to increase viral fitness in the Aedes albopictus vector (Tsetsarkin 
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et al., 2007; Vazeille et al., 2007), that, in turn, may expand the potential for CHIKV to diffuse 
to the Americas and Europe, due to the widespread distribution of this vector, in particular 
in Italy (Knudsen, 1995). In a previous paper we characterized 7 viral isolates (5 imported 
and 2 autochthonous cases), with respect to the molecular signatures of the Indian Ocean 
Outbreak in E1, particularly the A226V mutation. Imported cases included 3 returning from 
Mauritius in 2006 and 2 returning from India in 2006 and 2007, respectively; the 
autochthonous cases occurred during the 2007 Italian outbreak (Bordi et al., 2008).  CHIKV 
sequences of a 1013 bp fragment of E1 gene (nucleotide positions 10145-11158, respect to the 
reference strain S27) have been analyzed (Fig.2).  
All 7 isolates carried the M269V and D284E Indian Ocean signatures while the A226V 
mutation was present in all the isolates imported from Mauritius, in the autochthonous 
cases from the Italian outbreak and in the isolate imported from India in 2007, but was 
absent in the case imported from India in 2006.  
Our findings indicated that, during 2006 and 2007, multiple strains have been imported to 
Italy from countries where explosive Chikungunya outbreaks were ongoing. All the strains 
isolated in Italy, both imported and autochthonous, displayed two molecular signatures of 
 
 
Fig. 2. Phylogenetic tree of CHIKV strains performed on partial E1 gene 
CHIKV sequences of a 1013 bp fragment of E1 gene (nucleotide positions 10145-11158,  
respect to the reference strain S27) have been analyzed.  The strains isolated from human 
cases in Italy are in bold (Bordi et al., Clin Infect Dis, 2008) 
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the Indian Ocean outbreak (M269V and D284E). Concerning the A226V mutation, this was 
present in all imported and autochthonous cases, with the exception of the isolate imported 
from the Indian subcontinent in 2006. The absence of this mutation in the isolate imported in 
2006 from India was in agreement with published data (Arankalle et al., 2007), and with 
available GenBank sequence data, indicating that the virus strains circulating in India in 
2006 lacked this mutation.  
The presence of A226V in the isolate imported from India in July 2007 and in the isolates 
from the 2007 Italian outbreak (originating from a case imported from India) supports the 
view that the virus envelope sequence of strains from India changed over time, acquiring 
after 2006 the E1 mutation associated with enhanced fitness in Aedes albopictus. So it appears 
that the acquisition and fixation of the A226V mutation may be a common pathway of 
chikungunya explosion in epidemic areas, in a parallel interplay with the mosquito vector 
dynamics. Noteworthy, the outbreak in Singapore, where the A226V mutation was absent, 
has been rapidly controlled. 
10. Immune-pathogenesis 
Given the expanding geographic range of CHIKV and its potential to rapidly cause large 
scale epidemics, it has become important to understand the immune and pathogenic 
mechanisms active during CHIKV infections in order to guide the development of targeted 
and effective control and treatment strategies.  
In a review the possible interactions of the immune system with the different stages of the 
CHIKV life cycle have been discussed (Kam et al., 2009). The first encounter of CHIKV with 
human host is intradermal inoculation by the mosquito: replication of the virus starts at the 
site of inoculation. Different resident cell types are present in this location, including 
keratinocytes, dermal dendritic cells (DCs), Langerhans cells (LCs), and dermal 
macrophages, cells involved in the innate immune response. 
The innate immune response is the first barrier against viruses, being able to inhibit viral 
replication through cytolytic and non-cytolytic mechanisms. IFN system plays an important 
role in limiting virus spread at an early stage of infection. In vitro growth of all tested 
alphaviruses can be greatly suppressed by the antiviral effects of Interferon-/IFN-
when it is added to cells prior to infection, and, more specifically, CHIKV replication is 
significantly influenced by type I and II IFNs (Courderc et al., 2008; Schilte et al., 2010; 
Sourisseau et al., 2007). The finding that aberrant Type I interferon signalling in mice led to 
severe forms of CHIKF (Couderc et al., 2008) further highlighted important roles cytokines 
play in the pathology of CHIKV infection. Moreover, in a very recent study Wauquier and 
colleague demonstrated that CHIKV infection in humans elicit strong innate immunity 
involving the production of numerous proinflammatory mediators. Interestingly, high 
levels of Interferon IFN-α were consistently found. Production of interleukin (IL) 4, IL-10, 
and IFN-γ suggested the engagement of the adaptive immunity. This was confirmed by 
flow cytometry of circulating T lymphocytes that showed a CD8+ T lymphocyte response in 
the early stages of the disease, and a CD4+ T lymphocyte mediated response in the later 
stages (Wauquier et al., 2011). 
It was already known that skin cell fibroblasts were susceptible to CHIKV infection 
(Sourisseau et al.,2007); recently has also been demonstrated that CHIKV antigens could be 
detected in vivo in the monocytes of acutely infected patients (Her et al, 2010). CHIKV 
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interactions with monocytes, and with other blood leukocytes, induced a robust and rapid 
innate immune response with the production of specific chemokines and cytokines. In 
particular, high levels of IFN-were rapidly produced after CHIKV incubation with 
monocytes. The identification of monocytes during the early phase of CHIKV infection in 
vivo is significant as infected monocyte/macrophage cells have been detected in the synovial 
tissues of chronically CHIKV-infected patients, and these cells may behave as the vehicles 
for virus dissemination. This may explain the persistence of joint symptoms despite the 
short duration of viraemia  (Her et al., 2010). 
Since the A226V mutation has been associated with enhanced replication and fitness of 
CHIKV in A. albopictus vector and has also been shown to modulate cholesterol requirement 
for infection of insect cells (Tsetsarkin et al.,  2007), in a recent paper we investigated the 
possible involvement of A226V mutation in enhancing human pathogenesis in non vector 
hosts, by testing the replication competence in primate cell cultures of two isolates, differing 
for the presence or absence of this mutation (Bordi et al., 2011). We observed that the 
presence of A226V mutation did not influence the replication kinetics on primate cells. 
Moreover, the time course of appearance of cytopathic effect (CPE) and of cells 
immunostained with CHIKV-specific antiserum, was very similar for both the isolates, as 
well as the shape of the virus-positive multicellular foci, thus suggesting a similar 
mechanism of spread of the virus in the infected cell cultures.  
In addition, we considered the possibility that the A226V mutation could be associated with 
partial resistance to the inhibitory action of IFN- in classical experiments of inhibition of  
virus replication. Surprisingly, the A226V-carrying strain was more susceptible to the 
antiviral action of recombinant IFN-. (Fig.3) 
 
 
Fig. 3. Dose-dependent reduction of viral CPE by recombinant IFN-. 
In vitro experiments of inhibition of virus replication by recombinant IFN- on Vero E6 cells 
showing a dose-dependent reduction of CPE for both isolates: the A226V, carrying isolate 
and the wt (Bordi et al., New Microbiol, 2011). 
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Overall, our result did not support the concept that A226V mutation confers a replicative 
advantage in primate cell cultures, neither supported the possibility that partial resistance to 
the inhibitory action of IFN- could account for the explosive spread of the mutated strain 
in the human population in the countries where this mutation had occurred. However, the 
possibility that the interplay between the virus and the innate defence system may act at 
different levels of the virus/host interaction is to be taken into consideration, by exploring, 
for instance, other steps of the IFN response activation. 
At the moment, understanding CHIKV immuno-biology is still in its infancy and there is a 
long way to go before answers related to the interaction between virus and host immunity 
will be obtained. These will certainly be important in designing novel antiviral control 
strategies against the spread of CHIKV infection. 
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